Coronary heart disease(CHD), Hypertension(HBP), Heart failure(HF), Pulmonary hypertension(PH)
Conditions
Interventions
AMR >= 250:In patients with elevated AMR ( >= 250), intervention with a microcirculation improving agent (nicorandil) was performed and progressed One-year clinical and angiographic follow-up of the b
AMR <= 250:None
Observation group:None
Sponsors
People's Hospital of Xizang Autonomous Region
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Stage 1: Establish a cohort database of cardiovascular health status of people at different altitudes. Study population: cadres and people at different altitudes of plateau, regardless of nationality Stage 2: To establish a database of cardiovascular disease incidence and risk factors at different altitudes The inclusion criteria and data collection requirements for different diseases were as follows: cardiovascular disease: a. Coronary heart disease: ? previous diagnosis of coronary artery disease by coronary angiography or coronary CT, other than ECG abnormalities; 3) further examination of highly suspected patients. b. Heart failure: Heart failure is a pathophysiological state of patients with cardiovascular disease, rather than a disease. The diagnosis of heart failure depends on the evaluation of systolic or diastolic function of the patient's heart by echocardiography, and can not only rely on the patient's complaints or vital signs. c. Hypertension ? Patients with a definite diagnosis of hypertension and regular medication; ? two blood pressure systolic blood pressure >=140mmHg and/or diastolic blood pressure >= 90mmHg; d. Pulmonary hypertension: ? Echocardiography: tricuspid regurgitation velocity (TRV) >2.8m/s or pulmonary artery systolic pressure > 35mmHg; ? Chest CT showed signs of pulmonary hypertension. Stage 3:Study of coronary microcirculation at high altitude Inclusion criteria: 1) Age of 18-80 years old; 2) Coronary angiography if clinically suspected CAD; And 3) clear coronary angiography images for analysis. Stage 4: Methods and procedures for studying the mechanisms of coronary heart disease and hypertension using metabolomics and proteomics Patients diagnosed with hypertension, coronary heart disease.
Exclusion criteria
Exclusion criteria: 1.Cardiogenic shock or severe heart failure (NYHA>=III). 2.Creatinine >150µmol/L or Cockcroft-Gault formula estimated glomerular filtration rate <45; ml/kg/1.73 m2. 3.Allergic to iodinated contrast media. 4.woman during pregnancy. 5.The expected survival time was less than 1 year. 6.Low-quality angiography with poor vessel boundaries or contrast filling cannot be detected, or lesions with excessive overlap of stenosis segments or severely distorted vessels are not expected to perform QFR or AMR calculations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biochemical indicators (fasting blood glucose, blood routine, liver and kidney function, blood lipids, glycosylated hemoglobin, HCY, blood and urine ß2 microglobulin, urine microalbumin, three coagulation function tests, BNP, etc.);Imaging indicators (head and chest) CT;Echocardiography: left ventricular end-diastolic diameter and left ventricular ejection fraction, right ventricular diameter, presence or absence of tricuspid regurgitation and estimation of pulmonary artery pressure.;ECG;Angiographic indicators: a) anatomical characteristics of coronary angiographic lesions; b) baseline quantitative coronary angiography (QCA) analysis; c)QFR and AMR detection: offline analysis according to the patient's angiography.;Vital signs: such as blood pressure, heart rate, respiration, oxygen saturation;Laboratory indicators: such as blood, urine routine, fasting blood glucose, liver function (ALT), renal function (Cr), coagulation function, blood electrolytes, BNP results;Echocardiography: tricuspid regurgitation velocity (TRV) >2.8m/s or pulmonary artery systolic pressure > 35mmHg;; | — |
Countries
China
Contacts
Public ContactLuoBu-GeSang
People's Hospital of Xizang Autonomous Region
Outcome results
None listed